Phaseline

Companies › NKGen Biotech

NKGen Biotech: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Neurology; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SNK01
autologous natural killer (NK) cell therapy, patient-specific ex vivo expanded
–Phase 2Alzheimer Disease; Moderate Alzheimer DiseaseMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06189963SNK01Phase 1Moderate Alzheimer DiseaseNeurologyMar 2028
NCT07228078SNK01Phase 2Alzheimer DiseaseNeurologyApr 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Cytopeutics Sdn. Bhd. Sandoz Merz Pharmaceuticals Lupin Neurona Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.